Lupin Share Price
2083.00+0.00 (-0.72%)
+1.33% past 1 Year
Corporate filings & documents
Announcements
Intimation about participating in the Analyst/Institutional Investors Meet.
1 week agoIntimation about participating in the Analyst/Institutional Investors Meet.
1 week agoLupin Receives U.S. FDA Approval for Modafinil Tablets USP.
2 weeks agoLupin Receives U.S. FDA Approval for Modafinil Tablets USP.
2 weeks agoESG Rating by Crisil ESG Ratings & Analytics Ltd.
3 weeks agoESG Rating by Crisil ESG Ratings & Analytics Ltd.
3 weeks agoIntimation of allotment of 30967 equity shares under ESOP.
3 weeks agoIntimation of allotment of 30967 equity shares under ESOP.
3 weeks agoESG Rating by ESG Risk Assessment and Insights Limited.
3 weeks agoESG Rating by ESG Risk Assessment and Insights Limited.
3 weeks agoVISUfarma B.V. the Netherlands a wholly owned subsidiary of the Company has entered into an Exclusive License Agreement with Visus Therapeutics Inc. U.S.A.
1 month agoVISUfarma B.V. the Netherlands a wholly owned subsidiary of the Company has entered into an Exclusive License Agreement with Visus Therapeutics Inc. U.S.A.
1 month agoIntimation of Demise of Dr. Sofia Mumtaz President Legal & Compliance Canada ANZ & NEA Business a Senior Management Personnel of the Company.
1 month agoIntimation of Demise of Dr. Sofia Mumtaz President Legal & Compliance Canada ANZ & NEA Business a Senior Management Personnel of the Company.
1 month agoLupin Announces Approval from U.S. FDA for Pitolisant Tablets.
1 month agoLupin Announces Approval from U.S. FDA for Pitolisant Tablets.
1 month agoTranscript of Q1 FY2027 Earnings Conference Call
1 month agoTranscript of Q1 FY2027 Earnings Conference Call
1 month agoLupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
1 month agoLupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
1 month agoIntimation about participating in the Analyst/Institutional Investors Meet.
1 month agoIntimation about participating in the Analyst/Institutional Investors Meet.
1 month agoCopies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30 2026.
1 month agoCopies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30 2026.
1 month agoLink of Audio recording of the Earnings Call-Q1 FY27.
1 month agoLink of Audio recording of the Earnings Call-Q1 FY27.
1 month agoInvestor Presentation (Revised) - Q1 FY27 Results
1 month agoInvestor Presentation- Q1 FY2027
1 month agoInvestor Presentation- Q1 FY2027
1 month agoLupin Q1 FY2027 Results
1 month agoLupin Q1 FY2027 Results
1 month agoBoard Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoBoard Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoApproval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoApproval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026.
1 month agoDetails of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizers Report.
1 month agoDetails of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizers Report.
1 month agoProceedings of the Forty-Fourth Annual General Meeting held on August 04 2026.
1 month agoProceedings of the Forty-Fourth Annual General Meeting held on August 04 2026.
1 month agoLupin Announces the approval of Diazepam Injection USP in the United States.
1 month agoLupin Announces the approval of Diazepam Injection USP in the United States.
1 month agoLupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.
1 month agoLupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.
1 month agoSchedule of Earnings Call for Q1 FY27
2 months agoSchedule of Earnings Call for Q1 FY27
2 months agoLupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended June 30 2026.
2 months agoLupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended June 30 2026.
2 months agoLupin Inc. U.S.A. wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332 000 Common Shares of Kaveri Therapeutics Inc. U.S.A.
2 months agoLupin Inc. U.S.A. wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332 000 Common Shares of Kaveri Therapeutics Inc. U.S.A.
2 months agoCopy of Newspaper Advertisement relating to Annual General Meeting and e-voting related information.
2 months agoConcalls & investor presentations
Aug 2026
ConcallPresentation
Aug 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Nov 2025
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Feb 2025
Nov 2024
ConcallPresentation
Nov 2024
ConcallPresentation
Aug 2024
ConcallPresentation
Aug 2024
ConcallPresentation
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Nov 2023
ConcallPresentation
Nov 2023
ConcallPresentation
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Oct 2021
ConcallPresentation
Oct 2021
ConcallPresentation
Aug 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
Jan 2021
ConcallPresentation
Jan 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Nov 2020
ConcallPresentation